+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

  • ID: 3742634
  • Report
  • May 2016
  • Region: Global, Global
  • 74 Pages
  • La Merie Publishing
1 of 2
This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting CD20 in comparison with originator anti-CD20 antibodies to treat solid tumors as well as inflammatory diseases as of May 2016.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of CD20 targeting biosimilar and biosuperior antibodies for treatment of hematologic malignancies, rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Note: Product cover images may vary from those shown
2 of 2
1. 2015 Sales of Anti-CD20 Antibodies

2. Originator Anti-CD20 Antibodies
- Rituxan/MabThera Approved Indications & Pipeline
- Gazyva Approved Indications & Pipeline
- Arzerra Approved Indications and R&D Pipeline
- Zevalin Approved Indications

3. Biosuperior Anti-CD20 Antibodies
- 3rd Generation Anti-CD20 Antibodies
- Bispecific Anti-CD20 Antibodies
- Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

4. Biosimilar Anti-CD20 Antibodies
- Rituxan/MabThera Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
- Arzerra Biosimilar Antibodies

5. Corporate Anti-CD20 Biosimilar & Biosuperior Antibody Pipelines
Note: Product cover images may vary from those shown
3 of 2